Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.

NCT00619268 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT00619268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00619268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
February 29, 2012
Enrollment
160 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma